Completed PHASE1 INTERVENTIONAL 3-arm NCT01068925

Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers (ING)

An Open-Label, Single Sequence, Three-Period Drug Interaction Study of GSK1349572 and Tipranavir/Ritonavir in Healthy Adult Subjects (ING113096)

Sponsor: GlaxoSmithKline

Conditions HIV Infections Infection, Human Immunodeficiency Virus

Interventions GSK1349572

Updated 7 times since 2017 Last updated: Jun 20, 2019 Started: Feb 15, 2010 Primary completion: Apr 5, 2010 Completion: Apr 5, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on HIV Infections and Infection, Human Immunodeficiency Virus, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 7 data snapshots since 2010. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jul 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Jul 2019 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Feb 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
Shionogi
ViiV Healthcare

Data source: ViiV Healthcare

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Austin, United States